中华医学遗传学杂志
中華醫學遺傳學雜誌
중화의학유전학잡지
CHINESE JOURNAL OF MEDICAL GENETICS
2012年
4期
478-481
,共4页
卢凤民%佟子连%毛用敏%吴冬燕%许静
盧鳳民%佟子連%毛用敏%吳鼕燕%許靜
로봉민%동자련%모용민%오동연%허정
氯吡格雷%奥美拉唑%遗传多态性%CYP2C19基因
氯吡格雷%奧美拉唑%遺傳多態性%CYP2C19基因
록필격뢰%오미랍서%유전다태성%CYP2C19기인
Clopidogrel%Omeprazole%Genetic polymorphism%CYP2C19 gene
目的 探讨质子泵抑制剂奥美拉唑对于氯吡格雷抗血小板聚集作用的影响,并研究CYP2C19的基因多态性与氯吡格雷抗血小板聚集作用的关系.方法 将414例诊断为急性冠脉综合征且进行介入治疗的患者给予阿司匹林和氯吡格雷双联抗血小板治疗,术前及术前7天分别测定血小板聚集率( platelet aggregation,PA)后分别联用奥美拉唑(224例)和西咪替丁(190例)治疗,14天后再测定PA;应用聚合酶链反应-限制性片段长度多态性和DNA测序的方法对CYP2C19* 2(681 G/A)进行基因分型,分析基因多态性对氯吡格雷抗血小板作用的影响.结果 奥美拉唑组和西咪替丁组患者术前的PA比较差异无统计学意义,在术后7天和术后21天两组相同基因型患者PA比较差异无统计学意义,但术后7天、21天两组CYP2C19*2 GG型和GA型患者的PA明显小于AA型患者的PA,奥美拉唑组GG、GA、AA基因型术后7天的PA分别为(37.1±9.2)%、(37.4±9.4)%vs(45.6±8.9)%,术后21天的PA为(22.0±8.0)%、(22.6±7.2)%、(36.9±9.2)%,西咪替丁组GG、GA、AA基因型患者术后7天的PA为(38.4±8.3)%、(37.1±7.3)%、(48.5±7.2)%,术后21天的PA为(24.6±7.4)%、(22.9±7.7)%、(36.8±8.9)%(P<0.05).结论 奥美拉唑不影响氯吡格雷抗血小板效应.CYP2C19*2的AA基因变异影响氯吡格雷对血小板的抑制效果.
目的 探討質子泵抑製劑奧美拉唑對于氯吡格雷抗血小闆聚集作用的影響,併研究CYP2C19的基因多態性與氯吡格雷抗血小闆聚集作用的關繫.方法 將414例診斷為急性冠脈綜閤徵且進行介入治療的患者給予阿司匹林和氯吡格雷雙聯抗血小闆治療,術前及術前7天分彆測定血小闆聚集率( platelet aggregation,PA)後分彆聯用奧美拉唑(224例)和西咪替丁(190例)治療,14天後再測定PA;應用聚閤酶鏈反應-限製性片段長度多態性和DNA測序的方法對CYP2C19* 2(681 G/A)進行基因分型,分析基因多態性對氯吡格雷抗血小闆作用的影響.結果 奧美拉唑組和西咪替丁組患者術前的PA比較差異無統計學意義,在術後7天和術後21天兩組相同基因型患者PA比較差異無統計學意義,但術後7天、21天兩組CYP2C19*2 GG型和GA型患者的PA明顯小于AA型患者的PA,奧美拉唑組GG、GA、AA基因型術後7天的PA分彆為(37.1±9.2)%、(37.4±9.4)%vs(45.6±8.9)%,術後21天的PA為(22.0±8.0)%、(22.6±7.2)%、(36.9±9.2)%,西咪替丁組GG、GA、AA基因型患者術後7天的PA為(38.4±8.3)%、(37.1±7.3)%、(48.5±7.2)%,術後21天的PA為(24.6±7.4)%、(22.9±7.7)%、(36.8±8.9)%(P<0.05).結論 奧美拉唑不影響氯吡格雷抗血小闆效應.CYP2C19*2的AA基因變異影響氯吡格雷對血小闆的抑製效果.
목적 탐토질자빙억제제오미랍서대우록필격뢰항혈소판취집작용적영향,병연구CYP2C19적기인다태성여록필격뢰항혈소판취집작용적관계.방법 장414례진단위급성관맥종합정차진행개입치료적환자급여아사필림화록필격뢰쌍련항혈소판치료,술전급술전7천분별측정혈소판취집솔( platelet aggregation,PA)후분별련용오미랍서(224례)화서미체정(190례)치료,14천후재측정PA;응용취합매련반응-한제성편단장도다태성화DNA측서적방법대CYP2C19* 2(681 G/A)진행기인분형,분석기인다태성대록필격뢰항혈소판작용적영향.결과 오미랍서조화서미체정조환자술전적PA비교차이무통계학의의,재술후7천화술후21천량조상동기인형환자PA비교차이무통계학의의,단술후7천、21천량조CYP2C19*2 GG형화GA형환자적PA명현소우AA형환자적PA,오미랍서조GG、GA、AA기인형술후7천적PA분별위(37.1±9.2)%、(37.4±9.4)%vs(45.6±8.9)%,술후21천적PA위(22.0±8.0)%、(22.6±7.2)%、(36.9±9.2)%,서미체정조GG、GA、AA기인형환자술후7천적PA위(38.4±8.3)%、(37.1±7.3)%、(48.5±7.2)%,술후21천적PA위(24.6±7.4)%、(22.9±7.7)%、(36.8±8.9)%(P<0.05).결론 오미랍서불영향록필격뢰항혈소판효응.CYP2C19*2적AA기인변이영향록필격뢰대혈소판적억제효과.
Objective To investigate the impact of omeprazole on platelet response to clopidogrel and the effect of polymorphisms of CYP2C19 on the antiplatelet effect of clopidogrel. Methods Platelet aggregation (PA) was assessed before 300 mg aspirin plus 300 mg loading dose of clopidogrel and after 300 mg aspirin plus 75 mg maintenance dose of clopidogrel 7 days later in 414 patients with acute coronary syndrome who have undergone percutaneous coronary intervention (PCI). Thereafter,gastric mucosal protective drugs were given (omeprazolem 20 mg,n=224 or cimetidine 800 mg,n=190).Fourteen days later,PA was measured again.Genotypes of CYP2C19 * 2 were analyzed with polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).Results After taken aspirin and clopidogrel,PA has decreased significantly in both groups.Compared with cimetidine,omeprazole had no significant impact on PA on 7 and 21 days post PCI.Compared with homozygotes or heterozygotes for the wild-type CYP2C19 * 2,patients with CYP2C19 * 2 AA genotype had significantly higher PA on 7 and 21 days post PCI (P<0.05 ). Conclusion No attenuating effect on platelet response to clopidogrel has been observed for Omeprazole.The variant of CYP2C19 * 2 AA genotype is significantly associated with attenuated response to clopidogrel.